

Date and time: Monday 28 April 2014, 1000-1600

Minutes: Confirmed

Guideline Development Group Meeting 12 **Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (partial update)**

Place: Boardroom, NCGC, 180 Great Portland Street, London W1W 5QZ

Present: Paula D’Souza, Renal Community Nurse Specialist
Hugh Gallagher, Consultant Nephrologist (Acting Chair)
Kathryn Griffith, Principal in General Practice
Karen Jenkins, Consultant Renal Nurse
Paul Kendrew, Renal Pharmacist
Edmund Lamb, Consultant Clinical Biochemist
Robert Lewis, Consultant Nephrologist
Fiona Loud, Patient Member
Shelagh O’Riordan, Consultant in Geriatric & General Medicine
Nicholas Palmer, patient member
Paul Roderick, Professor of Public Health
Serena Carville, Associate Director, NCGC
Amelia Unsworth, Project Manager, NCGC (notes)
Dave Wonderling, Head of Health Economics, NCGC

Apologies: Paul Stevens, Consultant Nephrologist (GDG Chair)

In attendance:

NICE Staff: NICE attendee 1	Catharine Baden-Daintree, Senior Medical Editor	
NICE attendee 2	Ben Doak, Guidelines Commissioning Manager	
NICE attendee 3	Adrian Johnston, Costings Lead	

Observers:

None		
------	--	--

Notes

Notes

1. **Welcome and declarations of interest**

The acting chair welcomed the group to the twelfth meeting of this GDG.

Apologies were received from PS.

The acting chair reviewed and requested updates to the declarations of interest register.

FL declared that she received travel expenses from Amgen to attend an annual renal clinical directors' meeting to present on the Kidney Health project in April 2013, and travel and accommodation expenses from the International Society of Nephrology (ISN) to speak at their Nexus conference in Italy in May 2013. These were classified as standard reasonable meeting expenses. The acting chair agreed that no further action was required.

PDS declared that she attended an educational evening sponsored by Boeinger Ingelheim in October 2013. This was classified as standard reasonable meeting expenses. The acting chair agreed that no further action was required.

KG declared that she attended ACC in March 2014 with travel and accommodation sponsored by Boehringer Ingelheim. This was classified as standard reasonable meeting expenses. The acting chair agreed that no further action was required.

No other new declarations of interest were received and therefore no further action was required.

2. **Stakeholder consultation comments**

The GDG reviewed the stakeholder consultation comments and agreed changes to the draft recommendations.

3. **Research recommendations**

The GDG reviewed the draft research recommendations.

4. **Key priorities for implementation**

The GDG reviewed the key priorities for implementation.

5. **Spin-off publications**

The GDG was informed of the NICE policy on spin-off publications.

6. **Implementation plans**

The GDG was given a presentation on the implementation plans for the uptake of the guideline in clinical practice.

7. **Any other business**

None.

Date, time and venue of the next meeting

None.